NATICK, Mass., and PARIS--17 May--PRNewswire-AsiaNet/InfoQuest Boston Scientific's second generation stent compares favorably to market leading TAXUS Express2(TM) stent system, even with more complex lesions Boston Scientific Corporation (NYSE: BSX) today announced nine-month data from its TAXUS ATLAS clinical trial. The results confirmed safety and efficacy and demonstrated the excellent deliverability of the TAXUS(R) Liberte(TM) paclitaxel-eluting stent system compared to the TAXUS Express(TM)* and TAXUS Express2(TM) paclitaxel-eluting stent system. The Company made theannouncement at the annual Paris Course on Revascularization (EuroPCR) held this week in Paris. "The TAXUS ATLAS trial expands one of the largest DES data collections and extends the consistent clinical outcomes seen in the TAXUS clinical program to a new stent platform," said Mark A. Turco M.D., F.A.C.C., Director, Center for Cardiac and Vascular Research, Washington Adventist Hospital, Takoma Park, MD, and trials co-principle investigator. "The TAXUS Liberte stent providesimproved deliverability and conformability and the ATLAS trial results support excellent performance in complex lesions more consistent with evolving clinical practice patterns." The TAXUS ATLAS trial is a global, multi-center pivotal study comparing the TAXUS Liberte paclitaxel-eluting stent system to a case-matched control group of patients from the TAXUS IV and TAXUS V de novo studies who received respectively the TAXUS Express (1) and TAXUS Express2 paclitaxel-eluting stent system. The trial met its primary endpoint of nine-month target vesselrevascularization (TVR), a measure of the effectiveness of a coronary stent in reducing the need for a repeat procedure. The nine-month TVR rate for the TAXUS Liberte stent was 8.0 percent. The study also reported a target lesion revascularization (TLR) rate of 5.7 percent for the TAXUS Liberte stent. The TAXUS Liberte stent patients presented with more complex lesions compared to the control group. The percent of ACC/AHA B2/C lesions was 75.5 percent compared to 61.2 percent in the control patients (p